H. Lavallade

发表

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

D. Marin, L. Foroni, D. Milojković, 2012, Leukemia.

Vaccination Strategies in Lymphomas and Leukaemias

K. Rezvani, H. Lavallade, 2011, Drugs.

2 prior lines of TKI therapy failed patients with chronic myeloid leukemia in chronic phase who have Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in

K. Rezvani, J. Goldman, L. Foroni, 2013 .

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison

D. Blaise, M. Mohty, D. Coso, 2009, Leukemia.

Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening

C. Craddock, B. Shaw, M. Potter, 2016, Bone Marrow Transplantation.

Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study

J. Byrne, M. Copland, R. Clark, 2019 .

Chronic myeloid leukaemia

H. Lavallade, 2013 .

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

R. Bouabdallah, D. Blaise, M. Mohty, 2008, Bone Marrow Transplantation.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation

D. Blaise, M. Mohty, P. Viens, 2004, Bone Marrow Transplantation.

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

D. Blaise, M. Mohty, D. Coso, 2005, Leukemia.

Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission

R. Bouabdallah, D. Blaise, M. Mohty, 2006, Bone Marrow Transplantation.

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a “Donor” Versus “No Donor” Comparison.

D. Blaise, M. Mohty, D. Coso, 2007 .

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A “Donor” vs. “No Donor” Comparison.

R. Bouabdallah, D. Blaise, M. Mohty, 2006 .

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

D. Marin, J. Goldman, L. Foroni, 2009 .

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

D. Marin, J. Goldman, L. Foroni, 2010, Leukemia.

The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations

D. Marin, J. Goldman, M. Bua, 2007 .

Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience

G. Mufti, R. Benjamin, S. Norton, 2020, British journal of haematology.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.